Phaseline

Targets › IL1A

IL1A (Interleukin-1 alpha): drug programs, companies and trials

2 programs from 2 companies in 9 trials: 7 Phase 2, 1 Phase 1, 1 Phase 3; Oncology, Immunology; next expected readout Dec 2026.

Cytokine constitutively present intracellularly in nearly all resting non-hematopoietic cells that plays an important role in inflammation and bridges the innate and adaptive immune systems. After binding to its receptor IL1R1 together with its accessory protein IL1RAP, forms the high affinity interleukin-1 receptor complex. (UniProt, P01583)

Open in Phaseline: the race on IL1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AbbVieLutikizumab
Interleukin-1 alpha inhibitor; Interleukin-1 beta inhibitor
IL1A, IL1BPhase 3Hidradenitis Suppurativa; Rheumatoid Arthritis; Atopic Dermatitis; Ulcerative Colitis …Dec 2026
Centre Georges Francois LeclercXB2001
anti-IL-1α true human antibody
IL1APhase 1Metastatic Colorectal Cancer–

Conditions

Hidradenitis Suppurativa (3) Metastatic Colorectal Cancer (1) Rheumatoid Arthritis (1) Atopic Dermatitis (1) Ulcerative Colitis (1) Psoriatic Arthritis (1) Crohn's Disease (1)

Modalities

small molecule (1), antibody (1)

Companies

Centre Georges Francois Leclerc (1) AbbVie (1)

Related targets

IL1B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.